KE, XUE

Release date:2016-06-21  Release:


KE, XUE

Professor of Pharmaceutics

Director of Jiangsu province public technology service center of nanodrug preparation and evaluation

School of Pharmacy

Phone: 86-25-83271035

Email: kexue@vip.sina.com

Research Summary

Professor KE’s research focuses on the development of novel drug delivery systems and pharmaceutical technologies of biomacromolecule drugs and hydrophobic drugs.She has recently published about 20 SCI papers and takes on projects from Natural Science Foundation of China, State Project For Essential Drug Research and Development, etc.

Professor KE’s research also focuses on the formulation development of generic drugs. She has achieved technical transformation to industries up to forty pieces and obtained two pieces of Clinical Trial Permission of the first type of new drug.

Education

1999/09—2003/06

Ph.D., PharmaceuticsChina Pharmaceutical University

1994/09—1997/06

M.S.,  PharmaceuticsChina Pharmaceutical University

1990/09-1994/06

B.S.,   PharmaceuticsChina Pharmaceutical University

Academic Experience

1997- present     
Professor of Pharmaceutics, China Pharmaceutical University

2007/01—2010/12

Post Doc, Department of Life Sciences, Nanjing University

2013/01—2013/06

Drug Evaluation Scientist, State Center for Drug Evaluation

Awards and Honors

2011       New Century Excellent Researcher Award Program from Ministry of Education of China

2011       “333 high-level personnel training project  Young leaders in science and technology of Jiangsu Province

2007        Second in Science and Technology Progress Award of Jiangsu Province

Publications

[1] J.L. Tian, M.M. Han, Y.Wang, K.Qian, X. Ke*,T.Y.Ci,Reduction-responsive modification-induced higherefficiency for attenuation of tumor metastasis oflow molecular weight heparin functionalizedliposomes, RSC Advances, 6(2016), 49250.

[2] Y. Chen, J. Peng, M. Han, M. Omar, D. Hu, X. Ke*, N. Lu*, A low-molecular-weight heparin-coated doxorubicin-liposome for the prevention of melanoma metastasis, Journal of Drug Targeting, 23 (2015) 335-346.

[3] O. Mezghrani, Y. Tang, X. Ke*, Y. Chen, D. Hu, J. Tu*, L. Zhao, N. Bourkaib, Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin, International Journal of Pharmaceutics, 478 (2015) 553-568.

[4] J. Tian, L. Wang, L. Wang, X. Ke*, A wogonin-loaded glycyrrhetinic acid-modified liposome for hepatic targeting with anti-tumor effects, Drug Delivery, 21 (2014) 553-559.

[5] Y. Zhang, R. Luo, Y. Chen, X. Ke*, D. Hu, M. Han, Application of Carrier and Plasticizer to Improve the Dissolution and Bioavailability of Poorly Water-Soluble Baicalein by Hot Melt Extrusion, Aaps Pharmscitech, 15 (2014) 560-568.

[6] J. Li, H. Xu, X. Ke*, J. Tian, The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid, Journal of Drug Targeting, 20 (2012) 467-473.

[7] J.L. Tian, C. Tian, X. Ke*, Comparative evaluation of a co-processed self-lubricating excipient LubriTose SD as a direct compression vehicle, Journal of Drug Delivery Science and Technology, 22 (2012) 562-567.

[8] X. Dong, X. Ke*, Z. Liao, The microstructure characterization of meloxicam microemulsion and its influence on the solubilization capacity, Drug Development and Industrial Pharmacy, 37 (2011) 894-900.

[9] X. Ke*, J.H. Bei, Y. Zhang, J. Li, In vitro and in vivo evaluation of sanguinarine liposomes prepared by a remote loading method with three different ammonium salts, Pharmazie, 66 (2011) 258-263.

[10] J.L. Tian, X. Ke*, Z. Chen, C.J. Wang, Y. Zhang, T.C. Zhong, Melittin liposomes surface modified with poloxamer 188: in vitro characterization and in vivo evaluation, Die Pharmazie, 66 (2011) 362-367.